Valeant Pharmaceuticals International 8-K/A Results of Operations and Financial Condition

Exhibit 99.1

Valeant Pharmaceuticals International
Consolidated Balance Sheet and Other Data
(in thousands) Table 7

	September 30,		December 31,
	2005		2004
Balance Sheet Data
Cash and cash equivalents	$	369,818	$	222,590
Marketable securities		15,222		238,918
Total cash and marketable securities	$	385,040	$	461,508
Accounts receivable, net	$	168,611	$	171,860
Inventory, net		130,260		112,250
Long-term debt		789,721		793,139
Total equity		487,844		476,223

	Nine Months Ended
	September 30,			September 30,
	2005			2004
Other Data
Cash flow provided by (used in) continuing operations
Operating activities	$	67,501		$	37,933
Investing activities		(85,864	)		(170,147	)
Financing activities		173,661			(362,237	)
Effect of exchange rate changes on cash and cash equivalents		(8,070	)		1,082
Net increase (decrease) in cash and cash equivalents		147,228			(493,369	)
Net increase (decrease) in marketable securities		(223,696	)		91,298
Net decrease in cash and marketable securities	$	(76,468	)	$	(402,071	)